3 results
Approved WMOSuspended
To compare event-free survival (EFS) of the experimental treatment arm including ATO/ATRA and idarubicin with standard treatment based on ATRA plus chemotherapy (AIDA regimen).
Approved WMOCompleted
Primary objectives: Dose-expansion:To evaluate the antitumor activity of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in immunotherapy-naïve subjects with advanced or metastatic ccRCC as based on investigator assessed…
Approved WMOCompleted
1.To investigate COVID-19 vaccine responses of the standard schedule of 2 vaccinations with the Moderna mRNA-1273 vaccine (primary schedule) in patients with hematologic diseases, in particular those patients who are considered immunocompromised,…